Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Elicio Therapeutics, Inc. Director's Dealing 2021

Mar 10, 2021

33784_dirs_2021-03-10_8e0fa641-4f5c-4f99-ae46-64687a46eb25.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Angion Biomedica Corp. (ANGN)
CIK: 0001601485
Period of Report: 2021-03-08

Reporting Person: OMENN GILBERT S (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-03-08 Stock Option (Right to Buy) $15.01 A 15000 Acquired 2031-03-07 Common Stock (15000) Direct

Footnotes

F1: To vest on the earlier of the first anniversary of the date of grant or the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date.